Christian Weyer Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Christian Weyer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Christian Weyer. Christian Weyer is SVP, Research & Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and EVP Research and Development in INTERCEPT PHARMACEUTICALS INC ($ICPT) and EVP, Research & Development in INTERCEPT PHARMACEUTICALS, INC. ($ICPT) and See Remarks in FATE THERAPEUTICS INC ($FATE).
Latest Insider Trading Transactions of Christian Weyer
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMLN, FATE, ICPT
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 24.28 | 46 | 1,117 | 27,341 | 27.4 K to 27.3 K (-0.17 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 29.46 | 19,700 | 580,362 | 19,700 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 12,600 | 0 | 27,744 | 15.1 K to 27.7 K (+83.20 %) |
| Nov 30 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 37.27 | 357 | 13,305 | 15,977 | 16.3 K to 16 K (-2.19 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 46.52 | 46 | 2,140 | 16,737 | 16.8 K to 16.7 K (-0.27 %) |
| May 29 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 74.43 | 357 | 26,572 | 16,783 | 17.1 K to 16.8 K (-2.08 %) |
| Apr 29 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.95 | 181 | 15,557 | 17,140 | 17.3 K to 17.1 K (-1.04 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 58.40 | 46 | 2,686 | 17,321 | 17.4 K to 17.3 K (-0.26 %) |
| Feb 28 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 87.62 | 113 | 9,901 | 17,367 | 17.5 K to 17.4 K (-0.65 %) |
| Feb 28 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 85.39 | 357 | 30,484 | 17,480 | 17.8 K to 17.5 K (-2.00 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 99.66 | 7,900 | 787,314 | 7,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 94.04 | 723 | 67,991 | 17,837 | 18.6 K to 17.8 K (-3.90 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 4,800 | 0 | 18,560 | 13.8 K to 18.6 K (+34.88 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 123.92 | 54 | 6,692 | 13,760 | 13.8 K to 13.8 K (-0.39 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 123.92 | 364 | 45,107 | 13,814 | 14.2 K to 13.8 K (-2.57 %) |
| Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 54 | 3,172 | 2,883 | |
| Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 416 | 24,594 | 17,692 | |
| Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 123.24 | 1,581 | 194,842 | 14,178 | 15.8 K to 14.2 K (-10.03 %) |
| Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 54 | 3,172 | 15,759 | 15.7 K to 15.8 K (+0.34 %) |
| Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 416 | 24,594 | 15,705 | 15.3 K to 15.7 K (+2.72 %) |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 52 | 3,054 | 2,937 | |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 875 | 51,730 | 18,108 | |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 109.16 | 357 | 38,970 | 15,289 | 15.6 K to 15.3 K (-2.28 %) |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 101.65 | 1,040 | 105,716 | 15,646 | 16.7 K to 15.6 K (-6.23 %) |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 52 | 3,054 | 16,686 | 16.6 K to 16.7 K (+0.31 %) |
| Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 875 | 51,730 | 16,634 | 15.8 K to 16.6 K (+5.55 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 106 | 6,226 | 2,989 | |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 4,267 | 252,265 | 18,983 | |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 105 | 6,168 | 3,095 | |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 1,750 | 103,460 | 23,250 | |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 100.00 | 4,373 | 437,300 | 15,759 | 20.1 K to 15.8 K (-21.72 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 106 | 6,226 | 20,132 | 20 K to 20.1 K (+0.53 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 4,267 | 252,265 | 20,026 | 15.8 K to 20 K (+27.08 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 100.00 | 1,855 | 185,500 | 15,759 | 17.6 K to 15.8 K (-10.53 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 105 | 6,168 | 17,614 | 17.5 K to 17.6 K (+0.60 %) |
| Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 1,750 | 103,460 | 17,509 | 15.8 K to 17.5 K (+11.10 %) |
| Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 1,550 | 131,750 | 15,759 | 17.3 K to 15.8 K (-8.95 %) |
| Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 1,550 | 131,750 | 15,759 | 17.3 K to 15.8 K (-8.95 %) |
| Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 946 | 80,410 | 17,309 | 18.3 K to 17.3 K (-5.18 %) |
| Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 65.87 | 46 | 3,030 | 18,255 | 18.3 K to 18.3 K (-0.25 %) |
| Aug 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 60.50 | 357 | 21,599 | 18,301 | 18.7 K to 18.3 K (-1.91 %) |
| Aug 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 60.50 | 357 | 21,599 | 18,301 | 18.7 K to 18.3 K (-1.91 %) |
| Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 79.17 | 46 | 3,642 | 18,658 | 18.7 K to 18.7 K (-0.25 %) |
| May 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 87.83 | 357 | 31,355 | 18,704 | 19.1 K to 18.7 K (-1.87 %) |
| Apr 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 111.50 | 46 | 5,129 | 19,061 | 19.1 K to 19.1 K (-0.24 %) |
| Mar 01 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 103.16 | 333 | 34,352 | 19,107 | 19.4 K to 19.1 K (-1.71 %) |
| Mar 01 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 92.76 | 364 | 33,765 | 19,440 | 19.8 K to 19.4 K (-1.84 %) |
| Jan 18 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 110.80 | 6,800 | 753,440 | 6,800 | |
| Jan 18 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 4,200 | 0 | 19,804 | 15.6 K to 19.8 K (+26.92 %) |
| Jan 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 100.79 | 215 | 21,670 | 15,604 | 15.8 K to 15.6 K (-1.36 %) |
| Nov 29 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 113.78 | 1,343 | 152,807 | 15,819 | 17.2 K to 15.8 K (-7.83 %) |
| Nov 29 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 108.66 | 1,438 | 156,253 | 17,162 | 18.6 K to 17.2 K (-7.73 %) |
| Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Option Exercise | A | 58.74 | 3,200 | 187,968 | 3,200 | |
| Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Grant | A | 0.00 | 2,100 | 0 | 18,600 | 16.5 K to 18.6 K (+12.73 %) |
| Dec 11 2017 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Option Exercise | A | 59.12 | 25,000 | 1,478,000 | 25,000 | |
| Dec 11 2017 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Grant | A | 0.00 | 16,500 | 0 | 16,500 | 0 to 16.5 K |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See Remarks | Option Exercise | M | 1.37 | 25,000 | 34,250 | 258,040 | |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See Remarks | Buy | M | 1.37 | 25,000 | 34,250 | 30,429 | 5.4 K to 30.4 K (+460.49 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 0.00 | 35,000 | 0 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | H | 41.34 | 14,320 | 591,989 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | H | 36.90 | 12,516 | 461,840 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 24.87 | 16,027 | 398,591 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 22.60 | 144 | 3,254 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 18.85 | 833 | 15,702 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 18.01 | 19,340 | 348,313 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 16.54 | 2,930 | 48,462 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 16.02 | 123,758 | 1,982,603 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 15.03 | 113,027 | 1,698,796 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 9.02 | 13,748 | 124,007 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | H | 41.34 | 3,680 | 152,131 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | H | 36.90 | 1,484 | 54,760 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 24.87 | 3,973 | 98,809 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 22.60 | 937 | 21,176 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 19.79 | 1,208 | 23,906 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 18.01 | 7,360 | 132,554 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 16.54 | 2,633 | 43,550 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 16.02 | 6,242 | 99,997 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 15.03 | 11,973 | 179,954 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | J | 9.02 | 6,252 | 56,393 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 3,159 | 97,929 | 0 | 3.2 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 4,815 | 149,265 | 3,159 | 8 K to 3.2 K (-60.38 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 359 | 11,129 | 0 | 359 to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 886 | 27,466 | 0 | 886 to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 453 | 14,043 | 886 | 1.3 K to 886 (-33.83 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 1,012 | 31,372 | 0 | 1 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | J | 31.00 | 33,195 | 1,029,045 | 1,012 | 34.2 K to 1 K (-97.04 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 14.62 | 39 | 570 | 34,207 | 34.2 K to 34.2 K (+0.11 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 16.02 | 123,758 | 1,982,603 | 123,758 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 16.02 | 6,242 | 99,997 | 6,242 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 10,000 | 0 | 34,168 | 24.2 K to 34.2 K (+41.38 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 17.11 | 1,231 | 21,062 | 24,168 | 25.4 K to 24.2 K (-4.85 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 17.03 | 2,519 | 42,899 | 24,597 | 27.1 K to 24.6 K (-9.29 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 6,700 | 0 | 27,116 | 20.4 K to 27.1 K (+32.82 %) |
| Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 16.62 | 3,843 | 63,853 | 20,416 | 24.3 K to 20.4 K (-15.84 %) |
| Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 10,000 | 0 | 24,259 | 14.3 K to 24.3 K (+70.13 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 15.03 | 113,027 | 1,698,796 | 113,027 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 15.03 | 11,973 | 179,954 | 11,973 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 10,000 | 0 | 13,483 | 3.5 K to 13.5 K (+287.11 %) |
| Nov 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 13.42 | 1,314 | 17,634 | 3,357 | 4.7 K to 3.4 K (-28.13 %) |
Page: 1